ArticleAAPS PharmSciTech2008
Formation of inhalable rifampicin-poly(L-lactide) microparticles by supercritical anti-solvent process.
Article in AAPS PharmSciTech, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 59 citations in OpenAlex.
- Application of Quality by Design in the Development of Hydrogen Sulfide Donor Loaded Polymeric Microparticles.AAPS PharmSciTech · 2024Article
- PVP/aprepitant microcapsules produced by supercritical antisolvent process.Scientific reports · 2024Article
- Supercritical Antisolvent Technique for the Production of Breathable Naringin Powder.Pharmaceutics · 2022Article
- Dry Powder for Pulmonary Delivery: A Comprehensive Review.Pharmaceutics · 2020Review
- PLA/PLGA-Based Drug Delivery Systems Produced with Supercritical COPharmaceutics · 2020Review
- Glucosamine/L-lactide copolymers as potential carriers for the development of a sustained rifampicin release system usingHeliyon · 2019Article
- Supercritical Fluid Technology: An Emphasis on Drug Delivery and Related Biomedical Applications.Advanced healthcare materials · 2017Review
- Chitosan impregnation with biologically active tryaryl imidazoles in supercritical carbon dioxide.Journal of materials science. Materials in medicine · 2016Article
- 25-Hydroxyvitamin D(3)-loaded PLA microspheres: in vitro characterization and application in diabetic periodontitis models.AAPS PharmSciTech · 2013Article
- Improved bioavailability of a water-insoluble drug by inhalation of drug-containing maltosyl-β-cyclodextrin microspheres using a four-fluid nozzle spray drier.AAPS PharmSciTech · 2012Article
- Pharmaceutical aerosols for the treatment and prevention of tuberculosis.Frontiers in cellular and infection microbiology · 2012Review
- A novel preparation method for 5-aminosalicylic acid loaded Eudragit S100 nanoparticles.International journal of molecular sciences · 2012Article
- Application of supercritical antisolvent method in drug encapsulation: a review.International journal of nanomedicine · 2011Review
- Optimizing supercritical antisolvent process parameters to minimize the particle size of paracetamol nanoencapsulated in L-polylactide.International journal of nanomedicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Formation of inhalable microparticles containing rifampicin and poly(L-lactide) (L-PLA) by using supercritical anti-solvent process (SAS) was investigated. The solutions of drug and polymer in methylene chloride were sprayed into supercritical carbon dioxide. The effect of polymer content and operating conditions, temperature, pressure, carbon dioxide molar fraction, and concentration of solution, on product characteristics were studied. The prepared microparticles were characterized with respect to their morphology, particle size and size distribution, drug content, drug loading efficiency, and drug release characteristic. Discrete, spherical microparticles were obtained at high polymer:drug ratios of 7:3, 8:2, and 9:1. The shape of L-PLA microparticles became more irregular and agglomerated with decreasing polymer content. Microparticles with polymer content higher than 60% exhibited volumetric mean diameter less than 5 microm, but percent drug loading efficiency was relatively low. Drug-loaded microparticles containing 70% and 80% L-PLA showed a sustainable drug release property without initial burst release. Operating temperature level influenced on mean size and size distribution of microparticles. The operating pressure and carbon dioxide molar fraction in the range investigated were unlikely to have an effect on microparticle formation. An increasing concentration of feed solution provided larger size microparticles. Rifampicin-loaded L-PLA microparticles could be produced by SAS in a size range suitable for dry powder inhaler formulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.